"Use of tomato extract as antihypertensive agent and process for making water soluble sugar free tomato extract WO 2013163057 A1"
Adding blood pressure management to Fruitflow patent:-
"PATENT CITATIONS" "Cited Patent Filing date Publication date Applicant Title WO2010049707A2 * 2 Nov 2009 6 May 2010 Provexis Natural Products Limited Fruit extracts"
Adding blood pressure management to Fruitflow patent
"For example, a typical daily dosage regime for a human patient potentially at risk of suffering from high blood pressure may be from 0.0001 to 0.1 gram, e.g., in the range of 0.001 to 0.05 gram per kilogram body weight. When an active fraction is isolated and administered, the amount of solid material administered can be reduced by an amount consistent with the increased purity of the fraction. Typically, at least 100 mg (dry weight or dry weight equivalent), at least 200 mg, and usually at least 500 mg of the extract will be administered per day to a human patient. In some embodiments comprising administration of the compositions, the compositions are administered in single or multiple dosage units per day, for example, from one to four times daily, or from one or two times daily. Moreover, embodiments provide that the extracts of the invention are administered in solid, liquid, or semi-solid form. For example, the extracts are administered according to some embodiments in the form of tomato juice or concentrates thereof alone or in admixture with other fruit juices such as orange juice."
You specifically stated - revenue dried up this year due to increased cost of goods in the current year presumably with the FF2 launches.
The financial statement seems pretty clear - the reduction in revenue accruing to the Company for the year is primarily due to the high scale-up costs of the initial powder manufacturing setup phase for Fruitflow®.
These costs are now at an end such that the company by their own difinition now substantiate the onset of more material revenue streams. But as we have no knowledge of the AA, probably a pointless discussion.
Happy Xmas anyway. Will be back after the results when hopefully we are much more the wiser.
Blizzard - I stand by my statement that revenues to pxs did indeed dry up due to quote the statement "Revenues from profit sharing Alliance for the period £4k (2013: £37k) largely due to high scale-up costs in the initial powder manufacturing setup phase, which are now at an end" unquote.
It is the last part which intrigues me "which are now at an end" - at an end for DSM, but under the AA the statement does not specifically refer to pxs.Our profit in a profit share agreement as opposed to a royalty based one which bears no share of set up cost has been delayed.By how much and for how long is anyones guess.
Sorry but that is simply an untruth. Revenue did not "dry up" this year, in fact only in the first half of the last financial year was there no profit, and the reason for that was made very clear, and it was not in any way due to brand launches. That information is spelled out so that anyone can read it. Please don't invent your own reasons with nothing to substantiate your claims.
Datafeed and UK data supplied by NBTrader and Digital Look.
While London South East do their best to maintain the high quality of the information displayed on this site,
we cannot be held responsible for any loss due to incorrect information found here. All information is provided free of charge, 'as-is', and you use it at your own risk.
The contents of all 'Chat' messages should not be construed as advice and represent the opinions of the authors, not those of London South East Limited, or its affiliates.
London South East does not authorise or approve this content, and reserves the right to remove items at its discretion.